Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.47 |
| ▸ | QPCT | Q16769 | 3/20 | 0.46 |
| ▸ | QPCTL | Q9NXS2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951105 | 1.00 | PRKCI (0.53) | PRKCIKDM4EMAPTRAD52MMP12 | |
| SCHEMBL12488697 | 0.85 | ENPP2 (0.44) | PRKCIKDM4EMAPTRAD52MMP12 | |
| Hydrochloric Acid SCHEMBL29951513 | 0.83 | ENPP2 (0.43) | PRKCIKDM4EMAPTRAD52MMP12 | |
| SCHEMBL13086243 | 0.75 | PARP1 (0.63) | SMN1; SMN2 | |
| SCHEMBL25955980 | 0.75 | ENPP2 (0.42) | MAPTHDAC6ENPP2ALDH1A1HPGD | |
| Phenylboronic Acid SCHEMBL28818194 | 0.74 | CA4 (0.50) | PRKCIKDM4EMAPTRAD52MMP12 | |
| SCHEMBL30024579 | 0.74 | PRKCI (0.59) | PRKCIKDM4EMAPTRAD52MMP12 | |
| SCHEMBL352026 | 0.74 | PRKCI (0.59) | PRKCIKDM4EMAPTRAD52MMP12 | |
| SCHEMBL8634290 | 0.73 | QPCT (0.68) | PRKCIKDM4EMAPTRAD52MMP12 | |
| Hydrochloric Acid SCHEMBL28102177 | 0.72 | KDM4E (0.60) | PRKCIKDM4EMAPTRAD52MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130280245-A1 | 3-Aryl-6-aryl-[1,2,4]triazolo[4,3-alpha]pyridines as Inhibitors of Cell Proliferation and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2013-10-24 | — | — | US | claimed |
| US-20220119399-A1 | COMPOUNDS AND COMPOSITIONS THAT CAUSE MYCN AND/OR CMYC DEGRADATION AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-04-21 | — | — | US | disclosed |
| US-20200369665-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2020-11-26 | — | — | US | disclosed |
| EP-3645536-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2020-05-06 | — | — | EP | disclosed |
| CN-110809577-A | Modulators of adenosine A2A receptor | 雷沃医疗有限公司 | 2020-02-18 | — | — | CN | disclosed |
| WO-2019002606-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | SELVITA S.A. (PL) | 2019-01-03 | — | — | WO | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-7320995-B2 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1554272-B1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | LILLY CO ELI (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | EIL LILLY AND COMPANY (US) | 2005-12-08 | — | — | US | disclosed |
| EP-1554272-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004014900-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | PRKCI 3041/4885KDM4E 4221/4885MAPT 1627/4885 |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | MAP3K8, MAPK8, MAPK1 | PRKCI 296/4885KDM4E 2781/4885MAPT 1235/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | PRKCI 3041/4885KDM4E 4221/4885MAPT 1627/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | PRKCI 3041/4885KDM4E 4221/4885MAPT 1627/4885 |
| US-20220119399-A1 | COMPOUNDS AND COMPOSITIONS THAT CAUSE MYCN AND/OR CMYC DEGRADATION AND METHODS OF USE THEREOF | MYC, MYCBP, MYCBP2 | PRKCI 386/4885KDM4E 1796/4885MAPT 1899/4885 |
| US-20130280245-A1 | 3-Aryl-6-aryl-[1,2,4]triazolo[4,3-alpha]pyridines as Inhibitors of Cell Proliferation and the Use Thereof | MKI67, CCNI, CCNA1 | PRKCI 3538/4885KDM4E 1995/4885MAPT 3779/4885 |
| US-20200369665-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | PRKCI 1392/4885KDM4E 4607/4885MAPT 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.